EX-99.1
2
v054854_ex99-1.htm
EXHIBIT
99.1
ADVANCED BIOTHERAPY, INC.
Administration
c/o
KVG Partners
141
West Jackson Blvd., Suite 2182
Chicago,
Illinois 60604
Telephone
312-427-1912
Fax
312-427-5396
www.advancedbiotherapy.com
October
13, 2006
"FOR
IMMEDIATE RELEASE"
Advanced
Biotherapy, Inc. Completes Stock Sale and Debt
Conversion
Advanced
Biotherapy, Inc. announced today that it has completed the sale of common stock
to Richard P. Kiphart and other new investors in the amount of $5.4 million.
This investment, plus the previous $1.1 million invested by Richard P. Kiphart
around August 28, 2006, completes the $6.5 million capital raise previously
announced by the Company. The Company also announced the conversion of all
convertible notes, other promissory notes and accrued salaries owed by the
Company, except for a nominal amount which was paid out in cash. The Company
has
no long-term debt and has approximately $6.2 million in cash, as of October
12,
2006.
About
Advanced Biotherapy
The
Company, a pioneer in anticytokine therapy, has demonstrated the effectiveness
of its pioneering scientific strategy by conducting investigational clinical
trials treating patients suffering from AIDS, multiple sclerosis, rheumatoid
arthritis, corneal transplant rejection and certain autoimmune skin conditions,
including alopecia, all Th1 mediated autoimmune diseases which appear to have
the same proinflammatory Th-1 activity. Advanced Biotherapy is headquartered
in
Chicago with laboratories in Columbia, Maryland. The company has an extensive
patent portfolio including 7 issued patents.
Forward-Looking
Statements
Statements
made in this news release, other than statements of historical fact, are
forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated results
or
other expectations expressed in our forward-looking statements.
Some of
these forward-looking statements may be identified by the use of words in the
statements such as "anticipate", "estimate", "could" "expect", "project,"
"intend", "plan", "believe", "seek", "should", "may", "assume", "continue,"
variations of such words and similar expressions. These statements are not
guarantees of future performance and involve certain risks, uncertainties,
and
assumptions that are difficult to predict. Readers
are cautioned not to place reliance on these forward-looking statements, which
speak only as of the date the statements were made. See the Company's public
filings with the Securities and Exchange Commission for further information
about risks and uncertainties that may affect the Company and the results or
expectations expressed in our forward-looking statements.
Given
these risks and uncertainties, any or all of these forward-looking statements
may prove to be incorrect. Therefore, you should not rely on any such
forward-looking statements. Except as required under federal securities laws,
we
do not intend to update publicly any forward-looking statements to reflect
actual results or changes in other factors affecting such forward-looking
statements.
Page
1
Contact:
Advanced
Biotherapy, Inc.
Christopher
W. Capps - (312) 427-1912
www.advancedbiotherapy.com
Page
2

EX - 99 . 1 2 v054854 _ ex99 - 1 . htm EXHIBIT 99 . 1 ADVANCED BIOTHERAPY , INC . Administration c / o KVG Partners 141 West Jackson Blvd. , Suite 2182 Chicago , Illinois 60604 Telephone 312 - 427 - 1912 Fax 312 - 427 - 5396 www.advancedbiotherapy.com October 13 , 2006 " FOR IMMEDIATE RELEASE " Advanced Biotherapy , Inc . Completes Stock Sale and Debt Conversion Advanced Biotherapy , Inc . announced today that it has completed the sale of common stock to Richard P . Kiphart and other new investors in the amount of $ 5.4 million . This investment , plus the previous $ 1.1 million invested by Richard P . Kiphart around August 28 , 2006 , completes the $ 6.5 million capital raise previously announced by the Company . The Company also announced the conversion of all convertible notes , other promissory notes and accrued salaries owed by the Company , except for a nominal amount which was paid out in cash . The Company has no long - term debt and has approximately $ 6.2 million in cash , as of October 12 , 2006 . About Advanced Biotherapy The Company , a pioneer in anti cytokine therapy , has demonstrated the effectiveness of its pioneering scientific strategy by conducting investigational clinical trials treating patients suffering from AIDS , multiple sclerosis , rheumatoid arthritis , corneal transplant rejection and certain autoimmune skin conditions , including alopecia , all Th1 mediated autoimmune diseases which appear to have the same proinflammatory Th - 1 activity . Advanced Biotherapy is headquartered in Chicago with laboratories in Columbia , Maryland . The company has an extensive patent portfolio including 7 issued patents . Forward - Looking Statements Statements made in this news release , other than statements of historical fact , are forward - looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the anticipated results or other expectations expressed in our forward - looking statements . Some of these forward - looking statements may be identified by the use of words in the statements such as " anticipate " , " estimate " , " could " " expect " , " project , " " intend " , " plan " , " believe " , " seek " , " should " , " may " , " assume " , " continue , " variations of such words and similar expressions . These statements are not guarantees of future performance and involve certain risks , uncertainties , and assumptions that are difficult to predict . Readers are cautioned not to place reliance on these forward - looking statements , which speak only as of the date the statements were made . See the Company ' s public filings with the Securities and Exchange Commission for further information about risks and uncertainties that may affect the Company and the results or expectations expressed in our forward - looking statements . Given these risks and uncertainties , any or all of these forward - looking statements may prove to be incorrect . Therefore , you should not rely on any such forward - looking statements . Except as required under federal securities laws , we do not intend to update publicly any forward - looking statements to reflect actual results or changes in other factors affecting such forward - looking statements . Page 1 Contact : Advanced Biotherapy , Inc . Christopher W . Capps - ( 312 ) 427 - 1912 www.advancedbiotherapy.com Page 2